Immunic (NASDAQ:IMUX) Given “Buy” Rating at D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $17.00 price target on the stock.

Other analysts have also recently issued reports about the company. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright assumed coverage on shares of Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 target price for the company. Leerink Partners restated an “outperform” rating and issued a $5.00 price target on shares of Immunic in a research report on Monday, September 9th. StockNews.com cut shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. One analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Down 1.8 %

IMUX stock opened at $1.10 on Tuesday. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11. The business’s 50 day moving average is $1.14 and its 200-day moving average is $1.32. The firm has a market cap of $99.09 million, a P/E ratio of -0.89 and a beta of 1.88.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick acquired 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Immunic

Large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter worth about $50,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. State Street Corp grew its position in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.